In less than a year, the number of New York State residents receiving Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) prescriptions through Medicaid has nearly tripled. According to Dan O’Connell, director of the AIDS Institute at the New York State Department of Health, from July 2013 through June 2014, 305 HIV-negative New Yorkers were taking Truvada to prevent infection with the virus. By the close of February 2015, that figure had jumped 272 percent to 832 people.